Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 1, 2013, Pages 466-474

  Liu, Ping ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; FLUCONAZOLE;

ADULT; AGED; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CANDIDEMIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ESOPHAGUS CANDIDIASIS; FEMALE; HUMAN; INVASIVE CANDIDIASIS; LOADING DRUG DOSE; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MUCOCUTANEOUS CANDIDIASIS; MYCOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION EXPOSURE; POPULATION MODEL; PRIORITY JOURNAL; SIMULATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BODY WEIGHT; CANDIDA; CANDIDEMIA; CANDIDIASIS, INVASIVE; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG ADMINISTRATION SCHEDULE; ECHINOCANDINS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84872012549     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01473-12     Document Type: Article

References (19)

1. Pfizer. 2010. ERAXIS (anidulafungin), United States package insert. Pfizer Inc., New York, NY.
2. Bartlett MS, Current WL, Goheen MP, Boylan CJ, Lee CH, Shaw MM, Queener SF, Smith JW. 1996. Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo. Antimicrob. Agents Chemother. 40:1811-1816.
3. Moore CB, Oakley KL, Denning DW. 2001. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin. Microbiol. Infect. 7:11-16.
4. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ. 2008. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46:150-156.
5. Serrano MDC, Valverde-Conde A, Chavez MM, Bernal S, Claro RM, Peman J, Ramirez M, Martin-Mazuelos E. 2003. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp. Diagn. Microbiol. Infect. Dis. 45:131-135.
6. Benjamin DK, Jr, Driscoll T, Seibel NL, Gonzalez CE, Roden MM, Kilaru R, Clark K, Dowell JA, Schranz J, Walsh TJ. 2006. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob. Agents Chemother. 50:632-638.
7. Cohen-Wolkowiez M, Benjamin DK, Jr, Piper L, Cheifetz IM, Moran C, Liu P, Aram J, Kashuba AD, Capparelli E, Walsh TJ, Hope WW, Smith PB. 2011. Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. Clin. Pharmacol. Ther. 89:702-707.
8. Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. 2004. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J. Clin. Pharmacol. 44:590-598.
9. Dowell JA, Stogniew M, Krause D, Damle B. 2007. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J. Clin. Pharmacol. 47:461-470.
10. Dowell JA, Stogniew M, Krause D, Henkel T, Damle B. 2007. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J. Clin. Pharmacol. 47:305-314.
11. Andes D, Diekema DJ, Pfaller MA, Prince RA, Marchillo K, Ashbeck J, Hou J. 2008. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob. Agents Chemother. 52:539-550.
12. Krause DS, Simjee AE, van Rensburg C, Viljoen J, Walsh TJ, Goldstein BP, Wible M, Henkel T. 2004. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis. 39:770-775.
13. Krause DS, Reinhardt J, Vazquez JA, Reboli A, Goldstein BP, Wible M, Henkel T. 2004. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob. Agents Chemother. 48:2021-2024.
14. Vazquez JA, Schranz JA, Clark K, Goldstein BP, Reboli A, Fichtenbaum C. 2008. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. J. Acquir. Immune Defic. Syndr. 48:304-309.
15. Yano I, Beal SL, Sheiner LB. 2001. The need for mixed-effects modeling with population dichotomous data. J. Pharmacokinet. Pharmacodyn. 28:389-412.
16. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, Krause DS, Walsh TJ. 2007. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356:2472-2482.
17. Dodds ES, Drew RH, Perfect JR. 2000. Antifungal pharmacodynamics: review of the literature and clinical applications. Pharmacotherapy 20:1335-1355.
18. Theuretzbacher U. 2004. Pharmacokinetics/pharmacodynamics of echinocandins. Eur. J. Clin. Microbiol. Infect. Dis. 23:805-812.
19. NCCLS. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. Document M27-A. NCCLS, Wayne, PA.